Article info
PDFLetter
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial
- Correspondence to Dr H Bootsma, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, PO-Box 30.001, Groningen 9700 RB, The Netherlands; h.bootsma{at}umcg.nl
Citation
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial
Publication history
- Received April 6, 2013
- Revised July 22, 2013
- Accepted July 27, 2013
- First published August 12, 2013.
Online issue publication
December 30, 2013
Article Versions
- Previous version (12 August 2013).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions